Mauriac Syndrome: Isotopic Techniques and Genetic Analysis

Diabetes Mellitus Clinical Trial

Official title:

Genetic Analysis Coupled to Application of Isotopic Techniques to the Study of Mauriac Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04275141
• Other study ID #: NCT2019-01755
• Status: Completed
• Phase: N/A
• Start date: January 17, 2022
• Est. completion date: December 30, 2023

Study information

• Verified date: May 2024
• Source: University of Lausanne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mauriac syndrome (MS) is an entity of individuals combining poorly controlled diabetes mellitus type 1, short stature and glycogenic hepatopathy. Thus, the functional significance of Mauriac syndrome for glucose metabolism remains disputed, and whether genetic defects in glycogen metabolism contribute to glycogenic hepatopathy in MS remains to be clarified.Coupling the genetic analysis of targeted genes involved in glucose regulation with a dynamic exploration will eventually determine if a genetic abnormality leads to the disease and explains the nature of the phenotype.

Description:

Investigation of glucose homeostasis in MS, after an oral glucose load followed by exercise, using a quantitative measurement of the substrate flux. This dynamic in vivo kinetics can be explored using stable, nonradioactive tracers with the help of gas or liquid chromatography.

Investigation of genetic factors associated with MS phenotype. Molecular analysis will be performed by next generation sequencing (exome or whole genome sequencing). In addition, a targeted analysis for pathogenic variants in genes implicated in homeostasis regulation will be done.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: December 30, 2023
• Est. primary completion date: July 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Inclusion criteria for controls:

• DT1

• > 18 years old)

• Presence of at least one of the following auto-antibodies: anti-GAD65, anti-IAA, anti-ZnT8, anti-IA2 or ICA and/or low C-Peptide

• Insulin therapy by multiple daily injections or continuous subcutaneous insulin infusion by an insulin pump

• Informed consent as documented by signature

Inclusion criteria for subjects:

• Mauriac syndrome

• DT1

• > 18 years old

• Presence of hepatomegaly in infancy (confirmed = 1 abdominal US) at the time of diagnosis of Mauriac Syndrome

• Presence of short stature during infancy at the time of diagnosis of Mauriac Syndrome (<P3; WHO growth curves on = 2 different measures, at 2 different time-points)

• Presence of at least one of the following auto-antibodies: anti-GAD65, anti-IAA, anti-ZnT8, anti-IA2 or ICA and/or low C-Peptide

• Informed consent as documented by signature

Exclusion criteria for subjects and controls :

• Obesity (BMI = 30 kg/m2 or > 90th percentile)

• Illness that contraindicates physical activity

• Women who are pregnant or breast feeding

• Any clinically unstable disease

• Myocardial infarcts, syncope, heart rhythm disorder, unstable hypertension in the last 6 months

• Blood donation in the last 3 months for men and 4 months for women before the study

• Enrollment in a previous study less than 30 days before the start of the study

• Participation of the investigator, a family member, an employee or someone having a link with the investigator

Related Conditions & MeSH terms

• Diabetes Mellitus
• Dwarfism
• Glycogen Deposition
• Short Stature

Intervention

Other:
• oral glucose load
oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
• exercise test
oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min

Locations

Country	Name	City	State
Switzerland	Geneva University Hospital	Geneva
Switzerland	Lausanne University Hospitals	Lausanne	Vaud

Sponsors (2)

Lead Sponsor	Collaborator
University of Lausanne	University Hospital, Geneva

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	In vivo kinetics of ingested glucose	Plasma glucose kinetics [Time -90 min before ingestion of a test meal to Time 360 min after ingestion of a test meal]; Baseline : [Time -90min to Time 0min]; After an oral glucose load (60g): [Time 0min to Time 300min]; During exercise at fixed wattage (60W) for 30 min: [Time 300 min to Time 330 min]; After exercise for 30 min [Time 330 min to Time 360 min]; Trial stable isotope tracers ([U-13C6] glucose ingestion, will be used to assess ingested glucose flux at baseline and during the test.	Time -90 minutes to Time 360 minutes
Primary	In vivo kinetics of endogenous glucose	Plasma glucose kinetics [Time -90 min before ingestion of a test meal to Time 360 min after ingestion of a test meal]; Baseline : [Time -90min to Time 0min]; After an oral glucose load (60g): [Time 0min to Time 300min]; During exercise at fixed wattage (60W) for 30 min: [Time 300 min to Time 330 min]; After exercise for 30 min [Time 330 min to Time 360 min]; Trial stable isotope tracers [6,6-2H2] glucose infusion will be used to assess endogenous glucose flux at baseline and during the test.	Time -90 minutes to Time 360 minutes
Primary	In vivo kinetics of lactate	Plasma lactate kinetics [Time -90 min before ingestion of a test meal to Time 360 min after ingestion of a test meal]; Baseline : [Time -90min to Time 0min]; After an oral glucose load (60g): [Time 0min to Time 300min]; During exercise at fixed wattage (60W) for 30 min: [Time 300 min to Time 330 min]; After exercise for 30 min [Time 330 min to Time 360 min]; Trial stable isotope tracers [1-13C1]lactate infusion will be used to assess lactate flux at baseline and during the test.	Time -90 minutes to Time 360 minutes
Secondary	DNA Banking	10 ml of whole blood will be collected, at baseline, in two tubes EDTA 5ml for DNA extraction and banking in view of next generation sequencing (NGS) analysis.	At inclusion period